What is the recommended anti‑hepatitis C virus (HCV) treatment regimen in India for adults with confirmed infection?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 22, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Anti-HCV Treatment Regimens in India

For adults with chronic HCV infection in India, the recommended first-line treatment is sofosbuvir-based direct-acting antiviral (DAA) regimens, specifically sofosbuvir/velpatasvir for all genotypes or sofosbuvir/daclatasvir for genotype 3 (the most prevalent genotype in India), given for 12 weeks in non-cirrhotic patients.

Context for India

India has unique epidemiological characteristics that shape treatment recommendations:

  • Genotype 3 predominates (approximately 72% of cases), followed by genotype 1 (22%) and genotype 4 (6%) 1
  • Prevalence ranges from 0.5-1.5% nationally, with hotspots showing higher rates in northeast India, tribal populations, and parts of Punjab 2
  • Cost and accessibility are critical considerations for treatment selection

Treatment Regimens by Genotype

Genotype 3 (Most Common in India)

Primary recommendation:

  • Sofosbuvir (400 mg) + Daclatasvir (60 mg) daily for 12 weeks in treatment-naïve patients without cirrhosis 3, 1
  • Alternative: Sofosbuvir (400 mg) + Velpatasvir (100 mg) daily for 12 weeks 3, 4

For patients with cirrhosis or treatment-experienced:

  • Sofosbuvir + Daclatasvir (or Velpatasvir) for 24 weeks with ribavirin (1000-1200 mg based on weight) 3
  • If NS5A Y93H resistance mutation is present, add ribavirin and extend to 24 weeks 3

Real-world Indian data: SVR12 rates of 97.3% for genotype 3 with sofosbuvir/daclatasvir regimens, including patients with cirrhosis 1. Another Indian study showed 91.9% SVR12 with dual-DAA regimens in genotype 3 patients 5.

Genotype 1

Primary recommendation:

  • Sofosbuvir (400 mg) + Ledipasvir (90 mg) daily for 12 weeks 6, 1
  • Alternative: Sofosbuvir + Daclatasvir for 12 weeks

For cirrhotic patients:

  • Extend treatment to 24 weeks or add ribavirin for 12 weeks 6

Indian experience: 100% SVR12 achieved with sofosbuvir/ledipasvir in genotype 1 patients 1

Genotype 4

Primary recommendation:

  • Sofosbuvir (400 mg) + Ledipasvir (90 mg) daily for 12 weeks 6
  • Alternative: Paritaprevir/ritonavir/ombitasvir + ribavirin for 12 weeks 6

Indian data: 100% SVR12 with sofosbuvir-based regimens 1

Treatment Algorithm Based on Clinical Scenario

Step 1: Determine Genotype and Cirrhosis Status

  • HCV RNA quantification and genotyping
  • Assess for cirrhosis using transient elastography (FibroScan), APRI, or FIB-4 scores
  • If cirrhosis present, determine Child-Pugh class

Step 2: Select Regimen

Non-cirrhotic, treatment-naïve:

  • Genotype 3: Sofosbuvir/Daclatasvir × 12 weeks
  • Genotype 1: Sofosbuvir/Ledipasvir × 12 weeks
  • Genotype 4: Sofosbuvir/Ledipasvir × 12 weeks

Compensated cirrhosis (Child-Pugh A):

  • Genotype 3: Sofosbuvir/Daclatasvir × 24 weeks + ribavirin
  • Genotype 1: Sofosbuvir/Ledipasvir × 24 weeks OR 12 weeks + ribavirin
  • Genotype 4: Sofosbuvir/Ledipasvir × 12 weeks + ribavirin

Decompensated cirrhosis (Child-Pugh B/C):

  • Avoid protease inhibitors 3
  • Sofosbuvir/Ledipasvir or Sofosbuvir/Velpatasvir or Sofosbuvir/Daclatasvir × 12-24 weeks with low-dose ribavirin (start 600 mg, titrate as tolerated) 3

Treatment-experienced (prior DAA failure):

  • Consider sofosbuvir/velpatasvir/voxilaprevir (triple therapy) for 12 weeks 7

Critical Considerations

Ribavirin Dosing

  • Weight-based: 1000 mg if <75 kg, 1200 mg if ≥75 kg 6, 3
  • In decompensated cirrhosis: Start at 600 mg and increase as tolerated 3
  • Monitor hemoglobin; avoid if baseline <10 g/dL 6

Common Pitfalls to Avoid

  1. Don't use sofosbuvir/ledipasvir for genotype 3 - ledipasvir has poor activity against genotype 3 3
  2. Don't use protease inhibitors in decompensated cirrhosis (Child-Pugh B/C) 3
  3. Don't undertreate cirrhotic patients - they require longer duration or ribavirin addition
  4. Don't skip NS5A resistance testing in genotype 3 treatment failures - Y93H mutation affects treatment selection 3

Monitoring

  • HCV RNA at baseline, week 4 (optional for early virological response), end of treatment, and 12 weeks post-treatment (SVR12) 8
  • Monitor for HBV reactivation if HBsAg positive 9
  • Regular assessment of liver function and hemoglobin if on ribavirin

Special Populations

  • HIV coinfection: Same regimens, but check for drug-drug interactions with antiretrovirals 4
  • Post-transplant: Sofosbuvir/Ledipasvir + ribavirin × 12 weeks for genotype 1/4 in the allograft 6
  • Renal impairment (CrCl >30 mL/min): No dose adjustment needed 6

The high SVR rates (>90%) achieved in Indian real-world studies 1, 5, 10 demonstrate that these sofosbuvir-based regimens are highly effective and well-tolerated in the Indian population across all genotypes and disease stages.

References

Research

Treatment of chronic genotype-3 hepatitis C virus infection using direct-acting antiviral agents: An Indian experience.

Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology, 2017

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.